#China #Chengdu #Kelun-Biotech #TROP2 #sacituzumab tirumotecan

Kelun-Biotech's Sacituzumab Tirumotecan: A New Hope for Advanced TNBC Patients

In a groundbreaking development in the treatment of advanced triple-negative breast cancer (TNBC), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received acceptance from China's National Medical Products Administration (NMPA) for the review of a new indication application for sacituzumab tirumotecan (sac-TMT). This application seeks approval for sac-TMT to be used as a first-line therapy for patients with recurrent or metastatic TNBC, particularly those with a low programmed death ligand 1 (PD-L1) combined positive score (CPS) of less than 10, or those who have experienced a recurrence after earlier PD-1/PD-L1 treatments.

This milestone marks the sixth indication application for sac-TMT reviewed by the NMPA, reflecting the drug's promising potential in the oncology landscape. The foundation for this acceptance was laid by the positive outcomes observed in the multicenter Phase III OptiTROP-Breast03 study. This research assessed the efficacy and safety of sac-TMT compared to standard chemotherapy options in patients with unresectable, recurrent, or metastatic TNBC—who had not previously undergone systemic therapy for advanced disease. Results from this study indicated statistically significant and clinically meaningful improvements in treatment efficacy with sac-TMT.

A Necessary Advancement

Triple-negative breast cancer is notoriously difficult to treat and is characterized by the absence of three common receptors: estrogen, progesterone, and the human epidermal growth factor receptor 2 (HER2). Due to its aggressive nature, the treatment options available are quite limited, and traditional chemotherapy has often yielded subpar results. Thus, the introduction of effective new treatments is critically important.

Dr. Michael Ge, CEO of Kelun-Biotech, commented on the urgency of introducing new therapies for patients with PD-L1-negative advanced TNBC, noting that traditional chemotherapy options offer limited efficacy. He expressed optimism that the favorable results from the OptiTROP-Breast03 study validate the potential of sac-TMT as a more effective first-line treatment. The priority review status granted to this indication application is expected to expedite the approval process, possibly allowing this innovative treatment to reach patients much sooner.

Understanding Sacituzumab Tirumotecan (sac-TMT)

Sac-TMT is a novel antibody-drug conjugate (ADC) uniquely designed to target the TROP2 protein, which is commonly expressed in various solid tumors, including breast and lung cancers. The ADC mechanism employs a bifunctional linker that ensures effective delivery of its cytotoxic payload directly to tumor cells while also allowing for additional local cellular impact. The drug has already seen earlier approvals for various indications in China, particularly in treating TNBC after prior systemic therapies had failed.

Since its launch, sac-TMT has gained recognition as the first TROP2-targeted ADC approved for lung cancer, with multiple indications having been acknowledged by the NMPA. Currently, Kelun-Biotech's strategic collaboration with MSD (the trade name for Merck & Co., Inc., Rahway, NJ, USA) aims to extend the commercialization of sac-TMT beyond Greater China, creating further global opportunities for this promising treatment.

Looking Ahead

As of now, sac-TMT has four approved indications in China, indicating its therapeutic versatility and the potential to benefit multiple patient populations. The recent acceptance for review by the NMPA shows that Kelun-Biotech is intensively pushing forward with new trials and studies, contributing positively to the oncology field.

Both patients and practitioners eagerly await a positive outcome from the NMPA, as sacituzumab tirumotecan stands on the brink of becoming a vital first-line treatment option against advanced TNBC—addressing an urgent clinical need. This innovation could not only offer hope to those battling this challenging cancer but could also reshape the treatment landscape for solid tumors significantly.